Pharma Tech

Amberstone and Henlius agree to develop solid-tumour T-cell engagers

Sep 25, 2026, 9:10 AM

Read Full Article → Amberstone and Henlius agree to develop solid-tumour T-cell engagers

Translate article text

Choose a language and wait for the translated text.

Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.